NCT02198664 - Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2014

Primary Completion Date

January 4, 2018

Study Completion Date

January 4, 2018

Conditions

Peanut Allergy

Interventions

BIOLOGICAL

AR101 - Peanut protein capsule

Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)

Trial Locations (8)

10029

Mount Sinai Medical Center, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

25799

University of North Carolina Chapel HIll, Chapel Hill

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

72202

Arkansas Children's Hospital, Little Rock

75235

Children's Medical Center Dallas, Dallas

92123

UC San Diego, San Diego

02115

Boston Children's Hospital, Boston